Jan. 31 at 8:42 AM
$SPRO Sure, tebipenem will get approved for cUTI/pyelo but given the high bioavailability, it will be used for intra-abdominal, ENT, PNA, and diabetic foot infections in due time.
ESBL infections are only increasing.
Hospitals are losing money and at every budget meeting, length of hospital stay is always a major topic.
No brainer.
